NASDAQ OMX

Compuware zAdviser Delivers Actionable Analytic Insight to Continuously Improve Quality, Velocity and Efficiency on the Mainframe

Dela

Innovative Machine Learning Helps IT Leaders Pinpoint Opportunities to Boost DevOps Processes and Development Outcomes

 
  • Enterprises dependent on mainframe applications must aggressively improve DevOps quality, velocity and efficiency-even as responsibilities shift to less experienced internal teams and/or outsourcing partners.

  • Compuware is introducing zAdviser, a free product that leverages machine learning to help IT leaders make smarter data-driven decisions to drive continuous improvement of mainframe DevOps.

  • zAdviser identifies patterns that impact quality, velocity and efficiency as they pertain to mainframe development by analyzing a customer's Compuware product usage data and DevOps key performance indicators (KPIs).  

  • zAdviser is fueled by the ongoing collaboration between customers and Compuware, where customers contribute their relevant DevOps data and Compuware contributes their mainframe expertise and machine learning insights.

DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. Based on key performance indicators (KPIs), zAdviser measures application quality, as well as development velocity and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts. zAdviser is free for Compuware customers on current maintenance.

The KPIs were developed based on extensive research with customers and align with those published in the 2018 Forrester report, "Use Four Key Categories To Measure What Matters In Continuous Deployment."

zAdviser leverages a set of analytic models that uncover correlations between mainframe developer behaviors and mainframe DevOps KPIs. These correlations represent the best available empirical evidence regarding the impact of process, training and tooling decisions on digital business outcomes. With this empirical evidence and associated recommendations, managers can make high-impact decisions about their mainframe DevOps methods with vastly improved speed and confidence.

Enterprises that outsource mainframe development can also reap significant value from zAdviser by using the analytical results to continuously achieve better business outcomes over time.

Improvements in mainframe DevOps is an imperative for large enterprises, which are becoming more dependent on mainframe applications-not less. According to a recent Forrester Consulting study commissioned by Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. That percentage is expected to increase to 64 percent by 2019, while at the same time enterprises are failing to replace the expert mainframe workforce they have lost by attrition.

According to the study, "As mainframe workload increases-driven by modern analytics, blockchain and more mobile activity hitting the platform-customer-obsessed companies should seek to modernize application delivery and remove roadblocks to innovation."

The Forrester Consulting study also highlights the importance of responding to these challenges with empirical insight: "KPIs like mean lead time, number of epics per deployment, and metrics that drive automation will harness velocity and efficiency, even as the skills gap of the workforce expands." The full study can be accessed here.

Compuware has been helping their customers qualify, quantify and increase the value derived from their Compuware products through its Value Improvement Program (VIP) for over 15 years. zAdviser is the next step in the evolution of the VIP and evidence-based mainframe process improvement, leveraging these years of experience helping enterprises modernize mainframe DevOps and improve mainframe staff performance.

zAdviser data inputs include both 1) metrics captured from Compuware tools, including behavioral data relating to feature utilization and 2) data captured from the customer's DevOps toolchain.

By aggregating input from customer sites across industries and around the world, Compuware is building the industry's richest repository of mainframe DevOps data-which combined with advanced machine learning methods generates unmatched insight for enterprise IT leaders.

"Our mainframe applications continue to play a critical role in delivering an excellent customer experience," said Steve Kalkowski, Assistant Vice President, The Hartford. "A product like Compuware zAdviser will give us the advanced analytics we need to drive our efforts towards improving developer speed and quality as we transition to an agile delivery model."

Compuware today also announced a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.

"Enterprises cannot afford to be even slightly complacent about the speed and excellence with which they update and evolve the core business logic of their mainframe applications," said Compuware CEO Chris O'Malley. "With zAdviser, Compuware is now offering a powerful, fact-based resource for IT leaders at the world's largest corporations to lead their critical mainframe modernization efforts-and to thereby sustainably derive maximum business value from their investments in mainframe hardware, applications and talent."

To learn more about zAdviser and get involved, visit us here.

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com .

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Interim Report April - June 201815.8.2018 08:00Pressmeddelande

Second quarter 2018 Billing increased by 83 percent to SEK 33 (18) million. The Group's net sales increased by 75 percent to SEK 28 (16) million. The distribution between projects and web services (subscriptions) was 40/60 (60/40) percent. The gross margin increased to 86 (81) percent. The Group's operating profit improved to SEK -15 (-17) million. Basic earnings per share amounted to SEK -0.29 (-0.31). Cash flow from operating activities was SEK -18 (-15) million. The accumulated number of users increased to approximately 845,000. The accumulated number of downloads amounted to 25.5 million. The number of manufacturers was 1,230. The Board decided to initiate the process of listing the Company on Nasdaq Stockholm. Significant events during the second quarter BIMobject forms strategic partnership with Pipe Retail Solution to streamline digital planning of retail spaces. BIMobject signs Letter of Intent with leading US 3D media company Matterport. CEO's comments EQT Ventures' investment

BIMobject AB: Offentliggörande av delårsrapport april - juni 201815.8.2018 08:00Pressmeddelande

Den fullständiga rapporten finns även tillgänglig på bolagets hemsida (info.bimobject.com). Andra kvartalet 2018 Faktureringen ökade med 83 procent och uppgick till 33 MSEK (18). Koncernens nettoomsättning ökade med 75 procent och uppgick till 28 MSEK (16). Fördelning mellan projekt och webservices (prenumerationer) var 40/60 procent (60/40). Bruttomarginalen ökade till 86 procent (81). Koncernens rörelseresultat förbättrades och uppgick till -15 MSEK (-17). Resultat per aktie uppgick till -0,29 SEK (-0,31) före utspädning. Kassaflödet från löpande verksamheten uppgick till -18 MSEK (-15). Ackumulerat antal användare ökade och uppgick till cirka 845 000. Ackumulerat antal nedladdningar uppgick till 25,5 miljoner. Antalet tillverkare uppgick till 1230. Styrelsen beslutade att påbörja processen för notering av bolaget vid Nasdaq Stockholm. Viktiga händelser andra kvartalet BIMobject ingår samarbete med Pipe Retail Solution för att effektivisera digital butiksplanering. BIMobject tecknar

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Corline Biomedical AB: Läkemedelsverket ger tillstånd till klinisk prövning av Renaparin®6.8.2018 15:29Pressmeddelande

Corline Biomedical AB ("Corline") har i beslutsbrev från Läkemedelsverket erhållit tillstånd att genomföra klinisk prövning av läkemedelskandidaten Renaparin®. Läkemedelsverkets tillståndsmeddelande innebär att samtliga formella krav är uppfyllda för genomförande av studien RENAPAIR 01, som är en säkerhetsstudie i fas 1 omfattande totalt 18 patienter. Renaparin® är under utveckling för att förbättra njurtransplantation och administreras till njuren före transplantation i syfte att minska njurskador som annars kan uppstå då den mottagande patientens blodflöde kopplas ihop med donator-njuren. Corline meddelade i juni 2018 att man till Läkemedelsverket inlämnat ansökan om att få genomföra klinisk prövning av Renaparin® i en placebo-kontrollerad studie (RENAPAIR 01, Eudra-CT 2017-002075-25) där 9 patienter transplanteras med njurar som erhållit aktiv substans och 9 patienter får overksam placebo. Denna ansökan har nu godkänts av Läkemedelsverket. Studien inleds i Uppsala och genomförs däre

Cisco Schedules Conference Call for Q4 and Fiscal Year 2018 Financial Results1.8.2018 22:30Pressmeddelande

SAN JOSE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cisco has scheduled a conference call for Wednesday, August 15, 2018, at 1:30 PM (PT); 4:30 PM (ET) to announce its fourth quarter and fiscal year 2018 financial results for the period ending Saturday, July 28, 2018. Financial results will be released over GlobeNewswire via US National, European Technology Trade Media and Western Europe distribution circuits, after the close of the market on Wednesday, August 15, 2018. Cisco's quarterly earnings press release will be posted at www.cisco.com under the "Newsroom" section. Date: Wednesday, August 15, 2018 Time: 1:30 PM (PT); 4:30 PM (ET) To Listen via Telephone: 888-848-6507 212-519-0847 (for International Callers) RSVP: No RSVP is necessary To Listen via the Internet: We are pleased to offer a live and replay audio broadcast of the conference call with corresponding slides at https://investor.cisco.com. Replay: A telephone playback of the Q4 and FY2018 conference call is scheduled to be

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum